Related Experiment Videos
Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b
S R Schwid1, A D Goodman, D H Mattson
1Department of Neurology, University of Rochester, NY, USA.
Archives of Neurology
|October 6, 1997
Summary
Interferon beta-1b (IFN-beta-1b) therapy for multiple sclerosis (MS) may trigger autoimmune thyroid disease, specifically Graves disease. Monitor thyroid hormone levels in MS patients experiencing unexplained symptoms during IFN-beta-1b treatment.
Area of Science:
- Endocrinology
- Neurology
- Immunology
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Interferon beta-1b (IFN-beta-1b) is a common therapeutic agent for managing MS.
- Autoimmune conditions can be triggered or exacerbated by immunomodulatory therapies.
Observation:
- Two female patients with MS developed symptomatic autoimmune hyperthyroidism (Graves disease) after initiating IFN-beta-1b treatment.
- Symptoms included fatigue, depression, palpitations, heat intolerance, and weight loss, mimicking or overlapping with MS-related symptoms.
- Endocrinologic studies confirmed Graves disease in both cases.
Findings:
- This report details the first known cases of autoimmune thyroid disease associated with IFN-beta-1b therapy in MS patients.
- The findings suggest a potential link between IFN-beta-1b and the development of thyroid dysfunction.
- Similar adverse events, such as psoriasis, have been noted with interferon therapy for MS and hepatitis C.
Implications:
- Clinicians should consider monitoring thyroid hormone levels in MS patients undergoing IFN-beta-1b treatment, especially if constitutional symptoms arise.
- Distinguishing between MS-related symptoms and thyroid dysfunction is crucial for appropriate management.
- This highlights the importance of recognizing potential off-target effects of immunomodulatory therapies.